UnknownNot Applicable

Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers

South Korea100 participantsStarted 2016-06

Plain-language summary

Thrombotic biomarkers and angiographic characteristics were compared among the de novo patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV) and the control.

Who can participate

Age range

20 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CSC * neurosensory detachment in optical coherence tomography (OCT) * focal leakage in fluorescein angiography (FAG) and/or late choroidal hyperpermeability in indocyanine green angiography (ICGA) * PCV * subretinal and/or sub-retinal pigment epithelial fluid in OCT * branching vascular network and/or polyps in ICGA * Control * epiretinal membrane (ERM) * without underlying systemic, ophthalmic disease other than ERM Exclusion Criteria: * Previous history of using steroid (oral, topical) * Previous history of CSC/PCV * Previous history or evidence of intraocular inflammation including uveitis * Co-existing retinal or choroidal diseases * History of allergic reaction to fluorescein or indocyanine green dye * Underlying systemic conditions that could affect the thrombotic profiles (e.g. diabetes, hypertension, metabolic syndrome, coronary artery disease, cerebrovascular diseases, stroke, chronic renal failure, current smoker, pregnancy, sleep disorder)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Serum Fibrinogen in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum Factor VIII activity in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum Plasminogen activity in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum D-dimer in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum Fibrin degradation product in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum PAI-1 antigen in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum PAI-1 SNP genotyping in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Trial details

NCT IDNCT02815176

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-06

Contact for this trial

Se Woong Kang, MD

+82-2-3410-3548 swkang@skku.edu

View on ClinicalTrials.gov More Central Serous Chorioretinopathy trials

Who can participate

Age range

20 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Serum Fibrinogen in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum Factor VIII activity in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum Plasminogen activity in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum D-dimer in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum Fibrin degradation product in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum PAI-1 antigen in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis

Serum PAI-1 SNP genotyping in active PCV and CSC patients

Timeframe: Less than 1 week after initial diagnosis